New insights into intestinal hormone's role in promoting fat burning and weight loss in obese mice

A groundbreaking study reveals how the intestinal hormone FGF19 activates brain pathways to boost fat burning and promote weight loss in obese mice, opening new therapeutic possibilities for obesity and metabolic disorders.
Recent research has shed light on how a hormone produced by the intestine influences energy regulation and fat metabolism, offering promising avenues for obesity treatment. The hormone, known as fibroblast growth factor 19 (FGF19), activates mechanisms that enhance energy expenditure, stimulate fat burning, and help regulate blood glucose levels in obese mice. The study found that FGF19 acts on the hypothalamus, a critical brain region for maintaining energy balance, leading to increased activity of thermogenic fat cells that produce heat and burn calories.
The observed effects include not only improved metabolic functions but also reductions in peripheral inflammation and increased cold tolerance, which are essential for adaptive thermogenesis. Notably, these benefits were dependent on the activity of the sympathetic nervous system, which was shown to be crucial for FGF19's action.
The research team administered FGF19 directly into the brains of obese mice fed a high-fat diet, resulting in increased sympathetic nervous activity and boosted thermogenesis in white and brown adipose tissues. They also analyzed single-cell RNA sequencing data from the hypothalamus, identifying specific cell types that express FGF19 receptors, thus providing insight into the brain pathways involved.
These findings open new possibilities for developing drugs that mimic endogenous compounds like FGF19 to combat obesity and metabolic disorders such as diabetes. For instance, current therapies like semaglutide (Ozempic) operate by activating pathways that promote satiety, and future drugs could also target energy expenditure directly.
Furthermore, the study highlighted that FGF19's role extends beyond appetite regulation; it actively stimulates energy expenditure through thermogenesis, making it a promising target for comprehensive obesity management. The research was published in the American Journal of Physiology—Endocrinology and Metabolism and recognized as a top article in the journal.
Considering global obesity trends and their impact on non-communicable diseases, this discovery offers new hope for innovative treatments and highlights the importance of understanding brain-hormone interactions in energy regulation.
Source: https://medicalxpress.com/news/2025-06-intestinal-hormone-fat-weight-loss.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Early Life Factors and Their Role in Developing Multiple Sclerosis
Recent research highlights how childhood infections, stress, maternal age, and physical activity levels can influence the risk of developing multiple sclerosis later in life. Discover how early-life factors may impact MS development and prevention strategies.
Innovative Dual Action Immunotherapy Enhances CAR-T Cell Treatment for B-ALL
A novel dual-targeting CAR-T cell therapy shows promise in controlling B-cell acute lymphoblastic leukemia and reducing relapse by addressing immune escape mechanisms.
Using England's Diabetes Prevention Model to Inspire Canadian Initiatives
Canada aims to emulate England's successful diabetes prevention programs by launching community-based initiatives across provinces, potentially reducing cases and healthcare costs through proven diet and exercise strategies.
Improved Outlook for Crohn's Disease with Early Diagnosis and Advanced Treatments
New research indicates that early diagnosis and advanced biological treatments are leading to milder Crohn's disease symptoms and fewer surgeries, offering hope for improved patient outcomes.